ARVAIR

This brand name is authorized in Turkey

Active ingredients

The drug ARVAIR contains a combination of these active pharmaceutical ingredients (APIs):

1 Montelukast
UNII U1O3J18SFL - MONTELUKAST SODIUM

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Τhe CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis.

Read about Montelukast
2 Levocetirizine
UNII SOD6A38AGA - LEVOCETIRIZINE DIHYDROCHLORIDE

Levocetirizine, the ® enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.

Read about Levocetirizine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R06AK Combinations of antihistamines R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use
Discover more medicines within R06AK

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8680833091141, 8680833091158

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.